Oct 12 close
Kura Oncology's week centers on the planned formation of Caspian Therapeutics, with an investor webcast scheduled for 13 October to discuss the launch and present preclinical data for KO-7246, a menin inhibitor being studied in diabetes, including data from the European Association for the Study of Diabetes Annual Meeting. Separately, the company continues to advance ziftomenib, marketed as KOMZIFTI, which is approved for relapsed/refractory AML, alongside its global collaboration with Kyowa Kirin on commercialization. A technical analysis piece this week flagged an overall "Sell" signal based on indicators and moving averages.
Shares closed at $10.40, down 1.9%, sitting between the 50-day average of $11.30 and the 200-day average of $9.81, with the stock down 8.7% over one month but up 19.3% over six months. The GekkoIndex reads 65.6, placing it in the Accumulation zone. The stock trades 46.1% below Gekko Fair Value of $19.29.
Over the next 20 trading days, the company reports earnings on 3 November, 22 days away, falling inside a typical holding window. The last report, on 6 August, beat estimates and produced a 4% reaction, with 3 beats across the last 8 quarters. Insider buying over the past 90 days includes 2 open-market purchases totaling $2.4 million. Seasonality over this stretch has averaged -0.1% across 5 years, rising in 3 of them.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Kura Oncology scores 3 supportive, 2 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive2 mixed1 headwind
Averages disagree
Close $10.40 sits between the 50-day ($11.30) and 200-day ($9.81) averages, or the averages disagree.
See the chart65.6, Accumulation
Reading 65.6 is in the Accumulation zone.
See the GekkoIndex46.1% below
Price is 46.1% below Gekko Fair Value (more than 5% below).
See fair valueLeans bullish
Last 90 days: 2 open-market insider purchases.
See smart moneyReports in 22 days
Reports on Nov 3, 2026, 22 days away — inside a typical 20-trading-day hold.
See earnings−0.1% on average
From this point in the calendar, the next 20 trading days averaged −0.1% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Kura Oncology closed at $10.40 on Oct 12, 2026, +1.5% over the past year, inside a 52-week range of $7.36 to $13.90.
Use the left and right arrow keys to read daily values.
Put KURA on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Kura Oncology works on medicines aimed at treating cancer, operating as a clinical-stage biopharmaceutical business. Its furthest-along candidate is KOMZIFTI (ziftomenib), an oral small molecule designed to selectively and reversibly inhibit menin, and it is the company's first product to reach the commercial stage. Alongside this, the pipeline includes darlifarnib, under study in a Phase 1 human trial with several cohorts pairing it with other targeted therapies for large solid tumors, as well as KO-7246 and further next-generation menin inhibitors.
The company's research spans combination approaches, testing its compounds alongside other targeted therapies in solid tumor settings, while also exploring menin inhibition in the context of diabetes and cardiometabolic disorders. This points to a pipeline built around a core mechanism applied across multiple disease areas rather than a single indication.
Kura Oncology is headquartered in San Diego, California. Its shares are listed on the NASDAQ under the ticker KURA.
Kura Oncology’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 65.6, in the Accumulation zone, up 0.3 points over five sessions.
Up 0.3 points over five sessions.
Reading for Oct 12, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 48 | +4.8% | +5.1% | ||
| Accumulation (current zone) | 250 | −0.3% | −0.5% | ||
| Neutral | 363 | 0.0% | −0.4% | ||
| Distribution | 20 | −2.4% | −6.8% | ||
| Selling | 1 | Too few readings yet | |||
Average KURA share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
Kura Oncology trades 46.1% below Gekko Fair Value of $19.29, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Kura Oncology shares are worth, recalculated every trading day.
$19.29
Gekko Fair Value, Oct 10, 2026
46.1% Undervalued
At the end of Aug 2026 the price was 15.4% below the estimate.
Insiders filed 2 open-market purchases in Kura Oncology worth $2.35M, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
$2.35Min 2 open-market purchases
| Filed | Insider | Type | Value |
|---|---|---|---|
| Aug 24 | WILSON TROY EDWARD director, officer: President and CEO | Purchase | $1.24M |
| Aug 17 | Troy Edward Wilson President and CEO | Purchase | $1.11M |
From Form 4 filings, dated to when each was filed.
No trades in KURA were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
1of the funds Gekko tracks holds KURA.
Kura Oncology reports on Nov 3, 2026 (22 days away), and beat the EPS estimate in 3 of its last 8 reports.
Nov 3, 2026
22 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$0.77 est −$0.89 | — | +4.0% |
| May 12, 2026 | −$0.83 est −$0.90 | $18.27M est $25.97M | −0.3% |
| Mar 5, 2026 | −$0.92 est −$0.72 | $17.34M est $35.43M | +4.8% |
| Nov 4, 2025 | −$0.85 est −$0.57 | $20.75M est $51.43M | +1.7% |
| Aug 7, 2025 | −$0.75 est $0.15 | $15.29M est $64.95M | −8.1% |
| May 1, 2025 | −$0.66 est −$0.60 | $14.11M est $66.66M | −1.4% |
| Feb 26, 2025 | −$0.22 est −$0.64 | $53.88M est $57.96M | −2.9% |
| Nov 7, 2024 | −$0.63 est −$0.63 | — est $57.96M | −0.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Kura Oncology is $31.85, +206.3% from the last close, from 11 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 11 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 1 | J.P. Morgan | $30 | +188.5% |
| Sep 29 | Bank of America Securities | $31 | +198.1% |
| Sep 10 | Barclays | $28 | +169.2% |
| Sep 10 | Leerink Partners | $12.15 | +16.8% |
| Sep 10 | Lake Street | $23 | +121.2% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Oct 10, Kura Oncology averaged −0.1% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.4% | 1 of 5 |
| Next 10 trading days | −1.9% | 1 of 5 |
| Next 15 trading days | −1.8% | 2 of 5 |
| Next 20 trading days | −0.1% | 3 of 5 |
| Next 30 trading days | −0.1% | 3 of 5 |
For scale, KURA’s typical 20-trading-day move in either direction is about 10.6%.
Kura Oncology’s market cap is $922.8M and revenue of $77.23M over the last twelve months.
Coverage of Kura Oncology this week reads positive: 6 positive, 1 neutral and 1 negative headlines.
Kura Oncology’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Kura Oncology’s market cap is $922.8M at the Oct 12, 2026 close of $10.40, with 88.96M shares outstanding.
The consensus analyst 12-month price target for Kura Oncology is $31.85, +206.3% from the last close. Of the 11 firms that rated the stock in the last 90 days, 11 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Kura Oncology is undervalued: the Oct 12, 2026 close of $10.40 is 46.1% below Gekko Fair Value of $19.29. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Kura Oncology is expected to report on Nov 3, 2026 (22 days away). Analysts expect earnings of −$0.81 per share on revenue of $23.81M. Kura Oncology beat the earnings estimate in 3 of its last 8 reports, moving 3% on average across the report.
Kura Oncology’s 52-week high is $13.90 and its 52-week low is $7.36; it closed at $10.40 on Oct 12, 2026, +1.5% over the past year. Over the last five years the shares peaked at $24.17 on Mar 11, 2024.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (gekkoindex, fair value and smart money), 2 as mixed (trend and seasonality) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.